Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

Informations

Home » Informations
  • How to Develop Personalized Bladder-Preserving Strategies for MIBC? Professor Yijun Shen Shares MDT Experience and Clinical Decision Pathways

    From January 10 to 11, 2026, the Beijing Young Urologic Oncology Physicians Academic Exchange Conference was successfully held in Beijing. The meeting brought together leading experts and young physicians in urologic oncology to discuss cutting-edge scientific advances and real-world clinical challenges, with the goal of fostering academic innovation and supporting the development of young clinicians.

    2026.01.29
  • Professor Lei Fan: The Evolving Landscape and Future Directions of First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) | 2026 CSCO Hematologic Oncology Conference

    From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. During the conference, Professor Lei Fan from Jiangsu Provincial People’s Hospital presented a comprehensive overview of the latest advances, current standards, and future directions in first-line treatment for chronic lymphocytic…

    2026.01.29
  • Professor Erlie Jiang: Platform Synergy, Evidence Empowerment, and Grassroots Equity — Outcomes of the 2025 CSCO Leukemia Guideline Roadshow and the 2026 Strategic Blueprint

    From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. Guided by the overarching vision of “Greater Hematology, Greater Public Health, and Greater Health,” CSCO’s hematology committees have built a four-pillar framework centered on standardization, clinical support, collaboration, and prognostic…

    2026.01.29
  • Professor Lugui Qiu: Upholding Integrity, Driving Innovation—CSCO Myeloma Expert Committee 2025 Work Summary and 2026 Strategic Plan

    From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. As a malignant plasma cell disorder predominantly affecting older adults, multiple myeloma (MM) requires continuous advancement in standardized diagnosis, scientific innovation, and patient-centered management, all of which are critical to…

    2026.01.29
  • Annual Review | Professor Xiuli Ju: Advances in the Diagnosis and Treatment of Pediatric Mature B-Cell Lymphoma

    From January 16–18, 2026, the CSCO Leukemia, Lymphoma, and Myeloma Expert Committee Working Meeting and the 2026 CSCO Hematologic Oncology Conference were held in Haikou. Leading experts and scholars from across China presented advances in both basic and clinical research in leukemia, lymphoma, and myeloma, addressing key challenges in real-world practice and exploring new therapeutic…

    2026.01.29
  • Lymphoma Insights · ASH Special | Professor Qinqing Cai: New Advances in the Treatment of Relapsed/Refractory Marginal Zone Lymphoma

    The 2025 Annual Meeting of the American Society of Hematology (ASH 2025) recently concluded successfully in Orlando, USA. As the most influential annual event in hematology, this year’s meeting showcased multiple breakthrough advances in lymphoma, offering new directions for optimizing clinical practice.

    2026.01.29
  • Professor Thomas Powles: How Will ADC–Immunotherapy Combinations and ctDNA Reshape Perioperative Treatment in Bladder Cancer?

    The combination of antibody–drug conjugates (ADCs) and immune checkpoint inhibitors (ICIs) is rapidly transforming the clinical management of urothelial carcinoma. Meanwhile, circulating tumor DNA (ctDNA) is emerging as a highly promising biomarker, offering critical support for precision medicine and bladder-preserving treatment strategies.

    2026.01.28
  • Professor Xieqiao Yan: Optimizing Post-Failure Treatment Strategies in Renal Cell Carcinoma After Targeted-Immunotherapy—Exploring New Pathways for Later-Line Therapy

    From January 10 to 11, 2026, the Beijing Young Urologic Oncology Physicians Academic Exchange Conference was successfully held in Beijing. The meeting brought together leading experts and young physicians in urologic oncology to discuss cutting-edge scientific advances and key clinical challenges, with the goal of fostering academic innovation and supporting the growth of emerging clinicians.

    2026.01.28
«previous next»
Recent Posts
  • ASCO Voices from China | Professor Hao Zeng and Dr. Junru Chen: ORR Reaches 51.6% and DCR 96.8%—Bispecific Antibody Plus Targeted Therapy Opens a New Treatment Avenue for nccRCC
  • ASCO Spotlight | Professor Thomas Powles: Long-Term EV-302 Follow-Up Delivers Impressive Results, Bringing the Hope of Cure to Patients with Advanced Urothelial Carcinoma
  • Tracing ASCO | Professor Yijun Shen: China-Developed Immunotherapy–ADC Combinations Take the ASCO Stage, Reshaping the Future of Genitourinary Cancer Treatment
  • Professor Nengwang Yu’s Team at Qilu Hospital of Shandong University Reports a Novel Strategy to Enhance Bladder Cancer Chemotherapy
  • Academician Xu Zhang and Professor Jun Guo: Technological Innovation and the “Wisdom of China” Behind the Toripalimab Regimen Are Reshaping the Treatment Landscape of Urothelial Carcinoma
Recent Comments
    Archives
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top